Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome.

Source:http://linkedlifedata.com/resource/pubmed/id/17301813

Download in:

View as

General Info

Authors

Bal A, FAY EL, List AF, Boulware D, Widen R, Ryk EA, Epling-Burnette PK, Painter JS, Rollison DE, Vendron D

Affiliation

Immunology Program, H Lee Moffitt Cancer Center, Department of Interdisciplinary Oncology, University of South Florida, Tampa, FL 33612, USA. Pearlie.Burnette@moffitt.org

Abstract

Selected patients with Myelodysplastic Syndromes (MDS) are responsive to immunosuppressive therapy, suggesting that hematopoietic suppressive T cells have a pathogenic role in ineffective hematopoiesis. We assessed T-cell receptor (TCR) clonality through combined flow cytometry and molecular analysis of the complementarity determining region (CDR)-3 of the T-cell receptor-Vbeta gene. We identified clonal T cells in 50% of MDS patients (n=52) compared to 5% of age-matched normal controls (n=20). The presence of T-cell clones was not associated with features linked previously to immunosuppression response, including WHO diagnostic category, karyotype, marrow cellularity, IPSS category, sex or age <or=60. Using flow cytometry to identify expanded Vbeta-families, we found that T cells showed greater expansion in the bone marrow compared with peripheral blood, and were characterized as CD8(+)/CD57(+)/CD28(-) effector T cells. Expanded effector T cell were CD62L negative and expressed the natural killer C-lectin-family receptor NKG2D and CD244 (2B4). We conclude that clonal T-cell expansion is common among all MDS prognostic subgroups.

PMID
17301813

Publication types

Research Support, U.S. Gov't, Non-P.H.S.; Research Support, N.I.H., Extramural